J Korean Ophthalmol Soc.  2016 Jun;57(6):1018-1021. 10.3341/jkos.2016.57.6.1018.

Noninfectious Endophthalmitis after Intravitreal Injection of Aflibercept

• Kim CH
• Shin JS
• Jeon CY
• Chang YS
• Lee YH

• KMID: 2290509
• DOI: http://doi.org/10.3341/jkos.2016.57.6.1018

Abstract

PURPOSE
To report a case of noninfectious endophthalmitis after intravitreal injection of aflibercept.
CASE SUMMARY
A 67-year-old male patient presented with sudden vision loss 2 days after intravitreal aflibercept injection for neovascular age-related macular degeneration. Mild conjunctival injection and moderate inflammation in the anterior chamber were noted, but he had no ocular pain or hypopyon. The patient was diagnosed with noninfectious endophthalmitis and successfully treated with topical antibiotics and topical steroid eye drops. The infection was apparently cleared at 3 days. At 10 days after the initial presentation, his vision loss resolved completely.
CONCLUSIONS
Noninfectious endophthalmitis after intravitreal injection of aflibercept can be treated with topical steroids.

Keyword

Intravitreal aflibercept injection; Noninfectious endophthalmitis

MeSH Terms

Aged
Anterior Chamber
Anti-Bacterial Agents
Endophthalmitis*
Humans
Inflammation
Intravitreal Injections*
Macular Degeneration
Male
Ophthalmic Solutions
Steroids
Anti-Bacterial Agents
Ophthalmic Solutions
Steroids

Figure

• 

  Figure 1. Anterior segment photograph. (A) At 2 days after intravitreal aflibercept injection, slit lamp examination shows mild conjunctival injections and 2+ cells in the anterior chamber. Best corrected visual acuity was counting fingers at 1 m in the right eye. (B) At 1 month after intravitreal aflibercept injection, slit lamp examination shows decreased conjunctiva injections and no cell reactions in the anterior chamber. Best corrected visual acuity was 0.1 in the right eye.

Reference

References

1. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012; 119:2537–48.

2. Goldberg RA, Shah CP, Wiegand TW, et al. Noninfectious abdominal after intravitreal injection of aflibercept: clinical abdominal and visual outcomes. Am J Ophthalmol. 2014; 158:733–7.e1.

3. Hahn P, Chung MM, Flynn HW Jr, et al. Postmarketing analysis of aflibercept-related sterile intraocular inflammation. JAMA abdominal. 2015; 133:421–6.

4. Hahn P, Kim JE, Stinnett S, et al. Aflibercept-related sterile inflammation. Ophthalmology. 2013; 120:1100–1.e1–5.

5. Fine HF, Roth DB, Shah SP, et al. Frequency and characteristics of intraocular inflammation after aflibercept injection. Retina. 2015; 35:681–6.

6. Bakri SJ, Larson TA, Edwards AO. Intraocular inflammation abdominal intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2008; 246:779–81.

7. Kay CN, Tarantola RM, Gehrs KM, et al. Uveitis following abdominal bevacizumab: a noninfectious cluster. Ophthalmic Surg Lasers Imaging. 2011; 42:292–6.

8. Fauser S, Schroeder S, Caramoy A, et al. Intraocular inflammation after intravitreal ranibizumab injections. Acta Ophthalmol. 2011; 89:e98–9.

9. Sharma S, Johnson D, Abouammoh M, et al. Rate of serious abdominal effects in a series of bevacizumab and ranibizumab injections. Can J Ophthalmol. 2012; 47:275–9.

10. Sutter FK, Gillies MC. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol. 2003; 87:972–4.

11. Roth DB, Chieh J, Spirn MJ, et al. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol. 2003; 121:1279–82.

12. Nelson ML, Tennant MT, Sivalingam A, et al. Infectious and abdominal noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina. 2003; 23:686–91.

13. Damasceno N, Horowitz S, Damasceno E. Anterior uveitis after treatment ofage-related macular degeneration with ranibizumab and bevacizumab: uncommon complication. Clin Ophthalmol. 2012; 6:1201–5.

14. Cunningham MA, Tlucek P, Folk JC, et al. Sequential, acute noninfectious uveitis associated with separate intravitreal injections of bevacizumab and ranibizumab. Retin Cases Brief Rep. 2013; 7:355–8.

15. Celia F. Eylea's roaring rollout: though questions remain on long-term dosing, aflibercept has taken the retinal world by storm. Retinal Physician. 2012; 9:38–41.